Salicylamide derivative JMX0312 protects immunosuppressed Syrian hamsters against adenovirus lethal challenge

• Published in: Antiviral research Vol. 238; p. 106155
• Main Authors: Carretero-Ledesma, Marta, Li, Jun, Martín-Escolano, Javier, Herrera-Espejo, Soraya, Xu, Jimin, Chen, Haiying, Díaz-Navarro, Caridad, Pachón, Jerónimo, Sánchez-Céspedes, Javier, Zhou, Jia, Pachón-Ibáñez, María Eugenia
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2025
• Subjects: Adenovirus; Adenovirus Infections, Human - drug therapy; Adenovirus Infections, Human - prevention & control; Adenovirus Infections, Human - virology; Adenoviruses, Human - drug effects; Animals; Antiviral Agents - administration & dosage; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Antiviral drugs; Cricetinae; Disease Models, Animal; Humans; Immunocompromised Host; Immunosuppression; JMX0312; Liver - virology; Mesocricetus; Niclosamide; Syrian hamster; Viral Load - drug effects; Syrian hamster; Niclosamide; JMX0312; Immunosuppression; Adenovirus; Antiviral drugs

Despite the fact that human adenovirus (HAdV) causes severe infections in immunosuppressed and immunocompetent individuals, especially in children, there is currently no specific treatment for these infections. Previously we reported a new salicylamide analogue, JMX0312, as a potent inhibitor of HAd...